Active Substance: Zaleplon.
Overview
Welcome to Dwaey, specifically on SONATA 10mg page.
This medicine contains an important and useful components, as it consists of
Zaleplonis available in the market in concentration
Zaleplone
May precipitate new psychiatric abnormalities. Depression; hepatic impairment. History of drug or alcohol dependence or abuse, elderly and debilitated patients. Childn <18 yr. Pregnancy. May impair ability to drive or operate machinery. Do not take zaleplon if there is <4 hr of sleep. Dose reduction or withdrawal of drug should be done gradually.
Insomnia
Hypersensitivity. Severe hepatic impairment. Lactation.
>10% Headache (38%) 1-10% Dizziness (7-9%),Nausea (6-8%),Abdominal pain (6%),Weakness (5-7%),Dysmenorrhea (3-4%),Eye pain (3-4%),Amnesia (2-4%),Parasthesia (3%),Tremor (2%) <1% Fever,Photosensitivity,Anorexia,Colitis,Periphipheral edema,Amnesia,Anxiety,Depersonalization,Hallucination,Hypesthesia,Vertigo,Epistaxis,Abnl vision,Ear pain,Hyperacusis,Parosmia
3
Zaleplon, a pyrazolopyrimidine, is a sedative and hypnotic agent structurally unrelated to the benzodiazepines and other sedative-hypnotic agents. It is shown to interact with GABA subtype A complex by binding selectively to benzodiazepine type 1 receptor. It reduces sleep latency without affecting sleep duration.
Additive CNS effects may occur with CNS depressants e.g. TCA, alcohol, antihistamines, narcotic analgesics, thioridazine and diphenhydramine. Cytochrome P450 CYP3A4 inducers e.g. rifampicin, phenytoin, carbamazepine and phenobarbital decrease zaleplon concentrations. Increased zaleplon concentration with cimetidine and CYP 3A4 inhibitors e.g. erythromycin, ketoconazole.
Information not available